---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-24-000035"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T02:55:50.675916+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics: LNZ100 meets Phase 3 primary endpoint; 71% responder rate at 3 hours

## Summary
- Primary endpoint met: 71% of LNZ100 patients achieved ≥3-line improvement in near vision at 3 hours without distance loss (p<0.0001).
- Rapid onset: 71% achieved ≥3-line improvement at 30 minutes; long duration: 40% at 10 hours.
- No serious treatment-related adverse events in >30,000 treatment days across three trials.
- LNZ100 selected as lead candidate; company plans NDA submission to FDA in mid-2024.
- Patient survey: 90% reported near vision improvement; 75% would continue use post-study.

## SEC filing metadata
- accession: 0001815776-24-000035
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000035/0001815776-24-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000035/lenz-20240403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-24-000035
- JSON: https://secwatch.observer/filing/0001815776-24-000035.json
- Plain text: https://secwatch.observer/filing/0001815776-24-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.